Table 3.

Characteristics of patients with failure and relapse.

Characteristic		Failure		Relapse		P-value
		N	%	N	%
Total		60	100.0	14	100.0
Sex	Male	39	65.0	11	78.6	0.33
	Female	21	35.0	3	21.4
Age (years)a	>=35	38	63.3	10	71.4	0.57
	<35	22	36.7	4	28.6
HIV status	Negative	51	85.0	14	100.0	0.12
	Positive	9	15.0	0	0.0
Category	New	55	91.7	13	92.9	0.88
	Retreatment	5	8.3	1	7.1
BMI	≥18.5	20	33.3	3	21.4	0.39
	<18.5	40	66.7	11	78.6
Lung lesionsb	<50%	16	27.1	2	13.3	0.32
	≥50%	43	72.9	12	85.7
FLQ	Susceptible	32	76.2	11	91.7	0.47
	Low-level resistant	2	4.8	0	0.0
	High-level resistant	8	19.0	1	8.3
SLID	Susceptible	43	97.7	12	100.0	1
	Resistant	1	2.3	0	0.0
INH	Susceptible	1	2.2	0	0.0	1
	Resistant	44	97.8	11	100.0
PZA	Susceptible	9	33.3	2	33.3	1
	Resistant	18	66.7	4	66.7
PTH	Susceptible	2	12.5	0	0.0	1
	Resistant	14	87.5	5	100.0
EMB	Susceptible	1	12.5	0	0.0	1
	Resistant	7	87.5	1	100.0

BMI: body mass index in kg/m²; FLQ: fluoroquinolones; SLID: second-line injectable drugs; INH: isoniazid; PZA: pyrazinamide; PTH: prothionamide/ethionamide; EMB: ethambutol.

Numbers do not add up to column totals if there are missing data. The percentages refer to the displayed values excluding any missing. This is the case for Lung lesions among failures and for all drug susceptibility test results.

^aMean (median) age 33.9 (31.0) and 30.8 (28.0) for failure and relapse cases, respectively.

^bEach lung has been divided into three zones (superior, middle, inferior) by dividing the space between apex and hemi-diaphragm into three. The extent of lung lesions is defined as the proportion of zones affected among the 6 zones.